Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BCL9 | O00512 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3860603 | 0.78 | KCNJ1 (0.49) | MAPTALDH1A1LMNAADRB1SIRT6 | |
| SCHEMBL10345075 | 0.77 | DRD2 (0.50) | ALDH1A1KMT2A | |
| SCHEMBL5238412 | 0.77 | SSTR5 (0.39) | LMNA | |
| SCHEMBL2565915 | 0.75 | PTGS2 (0.51) | MAPTALDH1A1PKMKMT2APTGS2 | |
| SCHEMBL6283441 | 0.75 | FAAH (0.57) | MAPTKDM4EALDH1A1TDP1LMNA | |
| SCHEMBL23410201 | 0.73 | ADRB1 (0.45) | MAPTKDM4EALDH1A1TDP1BCL9 | |
| SCHEMBL6287099 | 0.72 | KCNJ1 (0.68) | MAPTKDM4EALDH1A1TDP1 | |
| SCHEMBL9211504 | 0.71 | TDP1 (0.46) | MAPTALDH1A1TDP1KMT2ALMNA | |
| SCHEMBL31177754 | 0.71 | PTGS2 (0.43) | KMT2APTGS2LMNAMAOBAOC3 | |
| SCHEMBL17481141 | 0.70 | CES2 (0.51) | MAPTALDH1A1BCL9CTNNB1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956046-B2 | 4-hydroxypiperidine derivatives having analgesic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-18 | — | — | US | disclosed |
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1391452-A1 | 4-HYDROXPIPERIDINE DERIVATIVE WITH ANALGETIC ACTIVITY | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176410-A1 | 4-hydroxpiperdine derivative with analgetic activity | HNMT, HDAC1, HDAC3 | MAPT 4853/4885KDM4E 2438/4885ALDH1A1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.